Table 1.
Safety and efficacy of combination treatment with anti-angiogenic therapy and anti-PD-1/PD-L1 antibody in patients with advanced HCC.
| Combinations | Number of patients | ORR (RECIST v1.1) | mPFS (months) | Grade 3/4 AE |
|---|---|---|---|---|
| apatinib + camrelizumab66 | 16 (2nd line) | 50% | 5.8 | NA |
| lenvatinib + pembrolizumab65 | 67 evaluable (63 as 1st line) | 40.3% | 9.5 | 80.6% |
| bevacizumab + atezolizumab49 | 104 (1st line) arm A | 36% | 7.3 | 38% |
| 60 (1st line) arm F1 | 20% | 5.6 | 37% | |
| axitinib + avelumab83 | 22 (1st line) | 13.6% | 5.5 | 72.7% |
| cabozantinib + nivolumab + ipilimumab84 | 35 (1st line) | 26% | 6.8 | 71% |
| cabozantinib + nivolumab84 | 36 (1st line) | 17% | 5.5 | 42% |
| lenvatinib + nivolumab85 | 30 (1st line) | 54.2% | 7.39 | 60% |
| regorafenib + pembrolizumab86 | 23 (1st line) | 30% | NA | NA |
ORR, objective response rate; mPFS, median progression-free survival; AE, adverse events; NA, not available.